June 20th 2025
Some of the companies that received American samples, FDA said, are partially owned or controlled by the Communist Party in China.
Europa Perspectives: EMA Transparency in Investigating CAR-T Secondary Cancers
February 28th 2024Steffen Thirstrup, chief medical officer, EMA, emphasizes the importance of transparency in investigating potential safety issues of CAR-T therapies, while highlighting the need to balance regulatory diligence with maintaining trust within the community and among stakeholders.